English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
抽象的な
Antibiotic Supplementation's Immunostimulatory Benefits on Asthma Patients: A Randomised, Double-Blind, Placebo-Controlled Trial
Dr. Clara Farrokhi
Background: Asthma is seen as an ongoing inflammatory condition of the airways. Living bacteria called probiotics are prevalent in the human stomach and have been shown to be protective against a variety of illnesses, including allergies. This study sought to better understand how probiotic treatment for asthma affected patients' clinical symptoms, changes in the expression pattern of specific microRNAs, and changes in plasma levels of IL-4 and IFN-.
Materials and methods: 40 asthmatic patients participated in the current investigation, which was a randomised,double-blind, placebo-controlled trial. Probiotics or a placebo was given orally once day for eight weeks. The expression of microRNAs, IL-4 and IFN- levels, and pulmonary function tests were evaluated before and after treatment.
Results: The findings demonstrated that probiotic supplementation dramatically decreased the expression of miR-16, miR146-a, and IL-4 levels in asthma patients while considerably increasing the expression of miR-133b.Furthermore, following taking probiotics, pulmonary function tests revealed a significantly improved Forced Expiratory Volume in 1 s and Forced Vital Capacity.
Conclusion: In our investigation, an 8-week probiotic supplementation regimen decreased IL-4 linked with Th2 cells and increased forced vital capacity and forced expiratory volume. The use of probiotics seems to be an option in addition to conventional asthma therapies.